KAPA Kairos Pharma: Bathi saben saham sajroning taun lumaku

Continuous capital outflow toward R&D in the absence of sales is driving a downward trend for Kairos Pharma Ltd (KAPA), and the relative EPS YoY TTM growth rate has settled at 31.30. This price action reflects the high cost of clinical phases and stringent regulatory oversight. Fundamental risk is tied to the outcomes of drug trials against resistant forms of cancer and the search for major strategic partners.
Kairos Pharma Limited - rincian analitis lan metrik utama (KAPA)

This indicator measures the percentage change in net earnings per share over a rolling year, allowing for an assessment of the actual scaling speed of business profitability. For Kairos Pharma Ltd (KAPA), whose model is based on the licensing of molecules without capital expenditures, the year-over-year EPS growth trend over the rolling period serves as the primary signal of the transition from capital burn to the monetization of intellectual property.